Médéric Mouterde

Médéric Mouterde

Auto-generated profile, based on publicly available information

Médéric Mouterde

Department of Genetics and Evolution (GENEV), University of Geneva , Geneva , Switzerland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2020 in Drug Safety
Verified
Journal Article
Open access
PDF file
VRVictoria Rollason
Victoria Rollason
MMMédéric Mouterde
Médéric Mouterde
Daali YoussefDaali Youssef
Daali Youssef
MČMartina Čížková
Martina Čížková
EPEdita Priehodová
Edita Priehodová
Jules DesmeulesJules Desmeules
Jules Desmeules
Introduction and Objective Cytochrome P450 enzymes are the major drug-metabolizing enzymes in humans and the importance of drug transport proteins, in particular P-glycoprotein, in the variability of drug response has also been highlighted. Activity of cytochrome P450 enzymes and P-glycoprotein can vary widely between individuals and genotyping and/or phenotyping can help assess their activity. Several phenotyping cocktails have been developed. The Geneva cocktail is composed of a specific probe for six different cytochrome P450 enzymes and one for P-glycoprotein and was used in the context of a research aiming at exploring genotypes and phenotypes in distinct human populations (NCT02789527). The aim of the present study is to solely report the safety results of the Geneva cocktail in the healthy volunteers of these populations. Materials and Methods The Geneva cocktail is composed of caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam, and fexofenadine. The volunteers fasted and avoided drinking caffeine-containing beverages or food and grapefruit juice overnight before receiving the cocktail orally. They provided blood spots for the probes’ concentrations at 2, 3, and 6 h after ingestion and were asked about adverse events. Results A total of 265 healthy adult volunteers were included from Ethiopia, Oman, and the Czech Republic. The mean plasma concentrations at the 2-h sampling time of each probe drug in the total sample were: 1663 ng/mL for caffeine, 8 ng/mL for bupropion, 789 ng/mL for flurbiprofen, 6 ng/mL for dextromethorphan, 2 ng/mL for midazolam, 35 ng/mL for fexofenadine, and 103 ng/mL for omeprazole. Four adverse events were observed representing an occurrence of 1.5%. All these events were categorized as mild to moderate, non-serious, and resolved spontaneously. A causal link with the cocktail cannot be excluded because of the temporal relationship but is at most evaluated as possible according to the World Health Organization-Uppsala Monitoring Centre causal assessment system. Conclusions In this research, healthy volunteers from three different human populations were phenotyped with the Geneva cocktail. Four adverse events were observed, confirming the safety of this cocktail that is given at lower than clinically relevant doses and therefore results in concentrations lower than those reported to cause adverse events.

30 November 2021 in American Journal of Biological Anthropology
Verified
Journal Article
Closed access
PDF file
IKIva Kulichová
Iva Kulichová
MMMédéric Mouterde
Médéric Mouterde
MMMohammed G. Mokhtar
Mohammed G. Mokhtar
IDIssa Diallo
Issa Diallo
PTPetr Tříska
Petr Tříska
VČViktor Černý
Viktor Černý

29 November 2022 in Genome Biology and Evolution
Verified
Journal Article
Open access
PDF file
MMMédéric Mouterde
Médéric Mouterde
Daali YoussefDaali Youssef
Daali Youssef
VRVictoria Rollason
Victoria Rollason
MČMartina Čížková
Martina Čížková
AGAnwar Mulugeta Gebremichael
Anwar Mulugeta Gebremichael
EPEstella S Poloni
Estella S Poloni
Variation in genes involved in the absorption, distribution, metabolism, and excretion of drugs (ADME) can influence individual response to a therapeutic treatment. The study of ADME genetic diversity in human populations has led to evolutionary hypotheses of adaptation to distinct chemical environments. Population differentiation in measured drug metabolism phenotypes is, however, scarcely documented, often indirectly estimated via genotype-predicted phenotypes. We administered seven probe compounds devised to target six cytochrome P450 enzymes and the P-glycoprotein (P-gp) activity to assess phenotypic variation in four populations along a latitudinal transect spanning over Africa, the Middle East, and Europe (349 healthy Ethiopian, Omani, Greek, and Czech volunteers). We demonstrate significant population differentiation for all phenotypes except the one measuring CYP2D6 activity. Genome-wide association studies (GWAS) evidenced that the variability of phenotypes measuring CYP2B6, CYP2C9, CYP2C19, and CYP2D6 activity was associated with genetic variants linked to the corresponding encoding genes, and additional genes for the latter three. Instead, GWAS did not indicate any association between genetic diversity and the phenotypes measuring CYP1A2, CYP3A4, and P-gp activity. Genome scans of selection highlighted multiple candidate regions, a few of which included ADME genes, but none overlapped with the GWAS candidates. Our results suggest that different mechanisms have been shaping the evolution of these phenotypes, including phenotypic plasticity, and possibly some form of balancing selection. We discuss how these contrasting results highlight the diverse evolutionary trajectories of ADME genes and proteins, consistent with the wide spectrum of both endogenous and exogenous molecules that are their substrates.

1 September 2025 in JMIR Preprints
Verified
Preprint
Open access
KMKateřina Maříková
Kateřina Maříková
JRJindra Reissigová
Jindra Reissigová
MVMiloslav Vilimek
Miloslav Vilimek
MCMarie Cerna
Marie Cerna
MPMarketa Pokorna
Marketa Pokorna
Kamila RasovaKamila Rasova
Kamila Rasova
BACKGROUND Spinal muscular atrophy (SMA) is a rare neuromuscular disease and the most common genetic cause of infant death. Although pharmacological treatment improves survival rates and functional capacity, physiotherapy remains a key component of care. A newly developed innovative equine-assisted physiotherapy method based on neuro-proprioceptive “facilitation and inhibition” principles (NEUROEQUIP-SMA), could potentially improve the quality and extent of motor development in children with SMA. OBJECTIVE The aim of the study is to compare NEUROEQUIP-SMA with standard physiotherapy and to evaluate its effect on functional outcomes and quality of life. In addition, the response of molecular biomarkers, such as long non-coding RNAs (lncRNAs), to treatment will be monitored. METHODS In this randomized, assessor-blinded controlled trial (NCT05341453), 16 children with SMA types I–III (aged 2–9 years) will be divided into two groups. Both groups will undergo a 6-day therapeutic program of equal duration and intensity. The intervention group will undergo NEUROEQUIP-SMA therapy, the control group will undergo standard physiotherapy, and both groups will undergo therapeutic grooming. Primary outcomes include motor coordination measured using 3D motion analysis, the presence of muscle fatigue (using surface EMG), spirometry, standardized tests and scaling tests. Secondary outcomes include monitoring of children's psychomotor development (home video analysis) and quality of life (the International Classification of Functioning, Disability and Health-based Documentation Form for the category "Children with Cerebral Palsy Brief”). LncRNAs will be analyzed from blood samples. Statistical analysis will be performed in R software. The study was approved by the Ethics Committee of the Third Faculty of Medicine, Charles University (ref.: 24.2.2022 and 6.3.2023). Informed consent was obtained from the legal representatives of the participants. RESULTS The study was initially designed for 8 participants. Data collection began in April 2022 and was completed in October 2024. Data analyses are planned for autumn 2025. Study results are expected to be available in 2026. The study is anticipated to be fully completed by the end of 2026. CONCLUSIONS This trial will be the first study to evaluate the effects of an equine-assisted physiotherapy intervention based on neuro-proprioceptive principles in children with SMA. If the intervention proves effective, it could expand physiotherapy options for this new generation of children receiving genetic therapies. It is also expected that the results of this study may contribute to the optimization of rehabilitation strategies that integrate biomechanical, clinical, and molecular perspectives. CLINICALTRIAL ClinicalTrials.gov NCT05341453; https://clinicaltrials.gov/study/NCT05341453.